Article Text

Download PDFPDF
Response to: ‘Patients with lupus with COVID-19: University of Michigan experience’ by Wallace et al
  1. Alexis Mathian,
  2. Zahir Amoura
  1. Sorbonne Université, Assistance Publique–Hôpitaux de Paris, Groupement Hospitalier Pitié–Salpêtrière, French National Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Other Autoimmune Disorders, Service de Médecine Interne 2, Institut E3M, Inserm UMRS, Centre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France
  1. Correspondence to Dr Alexis Mathian, Internal Medicine, University Hospital Pitié Salpêtrière, Paris 75651, France; alexis.mathian{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We thank Wallace and Waher1 for their interest in our study on the course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease 2019 (COVID-19) in a case series of patients with systemic lupus erythematosus (SLE) under long-term treatment with hydroxychloroquine (HCQ) and the reporting of their own case series.1 2 Their results corroborate those from our and other recently published observational studies in SARS-CoV-2-infected patients with SLE pointing to a lack of a preventive effect of HCQ,3 4 and furthermore underscore the notion that a high percentage of these patients suffer from several comorbidities.1 2 In their case series patients with SLE appeared to be more prone to obesity (80%), chronic obstructive pulmonary disease or asthma (60%), hypertension (20%), diabetes (20%), and chronic kidney disease (20%),1 …

View Full Text


  • Handling editor Josef S Smolen

  • Contributors AM and ZA wrote the response letter.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles